Why Alnylam Pharmaceuticals Is Crashing Today
Shares of Alnylam Pharmaceuticals (NASDAQ: ALNY) were tanking on Thursday after the company reported its earnings results for the third quarter. The biopharmaceutical company's stock is down 14.1% as of 1:34 p.m. EDT, likely due to the company missing revenue estimates for the quarter.
The company also announced its CEO, John Maraganore, will be retiring at the end of 2021.
Image source: Getty Images.
Source Fool.com
